Kairos Pharma Files for IPO
Ticker: KAPA · Form: S-1 · Filed: Jan 29, 2025 · CIK: 1962011
Sentiment: neutral
Topics: ipo, pharmaceutical, sec-filing
TL;DR
Kairos Pharma just filed for IPO, get ready for some new pharma stock.
AI Summary
Kairos Pharma, LTD. filed an S-1 form on January 29, 2025, indicating plans for an initial public offering. The company, based in Los Angeles, CA, operates in the pharmaceutical preparations sector. Financial details regarding the offering size or valuation are not yet disclosed in this initial filing.
Why It Matters
This S-1 filing signals Kairos Pharma's intention to become a publicly traded company, which could lead to increased investment and development in its pharmaceutical products.
Risk Assessment
Risk Level: medium — As a pre-IPO company in the pharmaceutical sector, Kairos Pharma faces inherent risks related to drug development, regulatory approval, and market competition.
Key Numbers
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
- 333-284569 — SEC File Number (SEC file number assigned to this filing)
Key Players & Entities
- Kairos Pharma, LTD. (company) — Filer of the S-1 registration statement
- 20250129 (date) — Filing date of the S-1 form
- 2355 Westwood Blvd. #139, Los Angeles, CA 90064 (address) — Business and mailing address of Kairos Pharma, LTD.
- 818-404-5541 (phone_number) — Business phone number for Kairos Pharma, LTD.
FAQ
What is the primary business of Kairos Pharma, LTD.?
Kairos Pharma, LTD. is in the business of Pharmaceutical Preparations, as indicated by its SIC code 2834.
When was this S-1 filing submitted?
The S-1 filing was submitted on January 29, 2025.
Where is Kairos Pharma, LTD. located?
Kairos Pharma, LTD. is located at 2355 Westwood Blvd. #139, Los Angeles, CA 90064.
What is the SEC file number for this registration?
The SEC file number for this registration is 333-284569.
What is the fiscal year end for Kairos Pharma, LTD.?
The fiscal year end for Kairos Pharma, LTD. is December 31.
Filing Stats: 4,575 words · 18 min read · ~15 pages · Grade level 13.7 · Accepted 2025-01-29 06:39:57
Key Financial Figures
- $0.001 — 5,000 shares of common stock, par value $0.001 per share ("common stock"), of Kairos P
- $1.40 — shares of common stock, exercisable at $1.40 per share, underlying common stock purc
- $5.5 million — receive proceeds of up to approximately $5.5 million upon the exercise for cash of the Warra
- $1.53 — rted sale price of our common stock was $1.53 per share. We recommend that you obtain
Filing Documents
- forms-1.htm (S-1) — 3162KB
- ex5-1.htm (EX-5.1) — 15KB
- ex23-1.htm (EX-23.1) — 4KB
- ex107.htm (EX-FILING FEES) — 23KB
- logo_01.jpg (GRAPHIC) — 5KB
- chart_001.jpg (GRAPHIC) — 198KB
- formdrs_001.jpg (GRAPHIC) — 118KB
- logo_001.jpg (GRAPHIC) — 9KB
- ex5-1_001.jpg (GRAPHIC) — 15KB
- 0001493152-25-004041.txt ( ) — 10127KB
- kapa-20240930.xsd (EX-101.SCH) — 49KB
- kapa-20240930_cal.xml (EX-101.CAL) — 48KB
- kapa-20240930_def.xml (EX-101.DEF) — 275KB
- kapa-20240930_lab.xml (EX-101.LAB) — 411KB
- kapa-20240930_pre.xml (EX-101.PRE) — 337KB
- forms-1_htm.xml (XML) — 1156KB
Risk Factors
Risk Factors 11 Special Note Regarding Forward-looking Statements 71
Use of Proceeds
Use of Proceeds 72 Determination of Offering Price 73 Dividend Policy 73
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 74
Business
Business 88 Management 118
Executive Compensation
Executive Compensation 123 Certain Relationships and Related Person Transactions 126 Principal Stockholders 127
Description of Capital Stock
Description of Capital Stock 128 Certain Material U.S. Federal Income Tax Consequences to Non-U.S. Holders of Our Common Stock 132 Selling Stockholders 135 Plan of Distribution 136 Legal Matters 137 Experts 137 Where You Can Find Additional Information 137 Index to Financial Statements F-1 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the SEC for the delayed or continuous offering and sale of securities pursuant to Rule 415 under the Securities Act. This prospectus generally describes Kairos Pharma, Ltd. and our common stock. The Selling Stockholders may use this registration statement to sell up to an aggregate of up to 6,425,000 shares of our common stock from time to time through any means described in the section entitled "Plan of Distribution." Our registration of the securities covered by this prospectus does not mean that either we or the Selling Stockholders will issue, offer or sell, as applicable, any of the securities registered hereunder. Under this registration statement, the Selling Stockholders may, from time to time, sell the securities offered by it described in this prospectus. We will not receive any proceeds from the sale of common stock by the Selling Stockholders pursuant to this prospectus, except for cash received upon any exercise of the Common Warrants offered hereunder, if any. We and the Selling Stockholders, as applicable, may deliver a prospectus supplement with this prospectus, to the extent appropriate, to update the information contained in this prospectus. The prospectus supplement may also add, update or change information included in this prospectus. You should read both this prospectus and any applicable prospectus supplement, together with additional information described below under the captions "Where You Can Find More Information." No offer of these securities will be made in any jurisdiction where the offer is not permitted. You shoul